Institutional investors hold a majority ownership of AMGN through the 83.14% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended March 2013, these large investors purchased a net $6.4 million shares.
| Mutual fund holders | 49.23% |
| Other institutional | 33.91% |
| Individual stakeholders | 0.59% |